Novo Nordisk channels '70s 'Magic' in first Ozempic TV ad by Beth Snyder Bulik Wednesday, August 1, 2018 Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.
ADA: AZ exec 'very optimistic' about Farxiga outcomes study by Eric Sagonowsky Wednesday, June 27, 2018 At ADA, an AstraZeneca executive said he's "very optimistic" about the company's cardiovascular outcomes study for Farxiga.
ADA: Trulicity bests Victoza, Bydureon in real-world study by Eric Sagonowsky Monday, June 25, 2018 Patients on Trulicity were more likely to continue therapy after a year than those on rival meds, according to data presented at ADA.
Novo scores Ozempic formulary coverage from top PBM by Eric Sagonowsky Friday, February 23, 2018 Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts.
AZ GLP-1 trailer Bydureon gets a facelift with BCise approval by Carly Helfand Monday, October 23, 2017 AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.
Why did AstraZeneca's Bydureon fail to cut CV risks? by Carly Helfand Thursday, September 14, 2017 Anyone looking for a heart-helping class effect from GLP-1 diabetes meds wouldn't be encouraged by the Bydureon data AstraZeneca rolled out Thursday.
AstraZeneca puts Brilinta, Bydureon on pay-for-performance bandwagon by Carly Helfand Tuesday, May 30, 2017 Pay-for-performance deals have been gaining popularity among drugmakers, and Harvard Pilgrim has been ready and willing to strike up partnerships. The latest to do so? AstraZeneca.
AZ's Bydureon clears heart test, but falls short of Novo rivals by Carly Helfand Tuesday, May 23, 2017 AstraZeneca finally has cardiovascular outcomes data for one of its top diabetes contenders. But the new results don’t measure up to rivals' studies.
AZ taps 3SBio to help drive sales of Byetta, Bydureon in China by Phil Taylor Thursday, October 13, 2016 AstraZeneca has licensed diabetes drugs Byetta and Bydureon to 3SBio to kickstart sales growth in China.
